Protect Yourself While There’s Still Time …

The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.

4 simple steps to protect your privacy and money before it’s too late.

Mario Germano Giuliani net worth and biography

Mario Giuliani Biography and Net Worth

Director of Royalty Pharma

Mr. Mario Germano Giuliani has been the President and Chief Executive Officer of Giuliani SpA. He has been the President at the firm since 2003 and Chief Executive Officer since 2000. Mr. Giuliani served as Chief Financial Officer of Giuliani SpA from 1999-2000.

From January 1998 to January 1999, Mr. Giuliani was an investment professional atVector Fund Management. He also co-founded Mosaix Ventures LP, in 2000. He also served at Giuliani SpA, Italy from 1996-1997 responsible for Marketing, Sales, Finance and Controlling. He is a Member of the Board of Directors of HBM Healthcare Investments AG. He also serves on several private company boards. He is a Director of Royalty Pharma since 2001. He served at Recordati SpA as Member of the Board of Directors since 2011.
Mr. Giuliani holds a degree in Economy and Commerce from the Catholic University of Sacred Heart and a Masters in Corporate Finance from Universit Commerciale Luigi Bocconi in Milan, Italy.

What is Mario Germano Giuliani's net worth?: The estimated net worth of Mario Germano Giuliani is at least $218.26 million as of December 5th, 2022. Mr. Giuliani owns 7,795,072 shares of Royalty Pharma stock worth more than $218,262,016 as of April 26th. This net worth evaluation does not reflect any other assets that Mr. Giuliani may own. Learn More about Mario Germano Giuliani's net worth.
How do I contact Mario Germano Giuliani?: The corporate mailing address for Mr. Giuliani and other Royalty Pharma executives is 110 E 59th Street, New York NY, 10022. Royalty Pharma can also be reached via phone at 212-883-0200 and via email at [email protected]. Learn More on Mario Germano Giuliani's contact information.
Has Mario Germano Giuliani been buying or selling shares of Royalty Pharma?: Mario Germano Giuliani has not been actively trading shares of Royalty Pharma during the last ninety days. Most recently, Mario Germano Giuliani sold 84,302 shares of the business's stock in a transaction on Monday, December 5th. The shares were sold at an average price of $43.15, for a transaction totalling $3,637,631.30. Following the completion of the sale, the director now directly owns 7,795,072 shares of the company's stock, valued at $336,357,356.80. Learn More on Mario Germano Giuliani's trading history.
Who are Royalty Pharma's active insiders?: Royalty Pharma's insider roster includes Terrance Coyne (CFO), Henry Fernandez (Director), William Ford (Director), Mario Giuliani (Director), Pablo Legorreta (CEO), George Lloyd (EVP), James Reddoch (EVP), Rory Riggs (Director), Sanjay Singh (CRO), and Marshall Urist (EVP). Learn More on Royalty Pharma's active insiders.
Are insiders buying or selling shares of Royalty Pharma?: In the last twelve months, Royalty Pharma insiders bought shares 4 times. They purchased a total of 485,388 shares worth more than $15,543,025.16. In the last twelve months, insiders at the biopharmaceutical company sold shares 8 times. They sold a total of 2,250,753 shares worth more than $72,415,950.97. The most recent insider tranaction occured on January, 4th when Director Rory B Riggs sold 35,702 shares worth more than $983,590.10. Insiders at Royalty Pharma own 18.7% of the company. Learn More about insider trades at Royalty Pharma.
Information on this page was last updated on 1/4/2024.

Mario Germano Giuliani Insider Trading History at Royalty Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/5/2022	Sell	84,302	$43.15	$3,637,631.30	7,795,072
12/1/2022	Sell	165,000	$44.10	$7,276,500.00	22,225,000
9/28/2022	Sell	32,593	$41.05	$1,337,942.65	8,077,140
9/21/2022	Sell	125,697	$41.25	$5,185,001.25	8,321,113
9/19/2022	Sell	232,185	$41.50	$9,635,677.50	22,657,815
9/16/2022	Sell	154,986	$41.72	$6,466,015.92	22,890,000
9/7/2022	Sell	261,881	$42.66	$11,171,843.46	8,814,759
8/25/2022	Sell	500	$44.00	$22,000.00	9,076,640

Mario Germano Giuliani Buying and Selling Activity at Royalty Pharma

Royalty Pharma Company Overview

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Today's Range

Now: $28.00

$27.81

$28.27

50 Day Range

MA: $29.65

$27.46

$31.33

2 Week Range

Now: $28.00

$25.92

$35.76

Volume

1,358,520 shs

Average Volume

2,670,692 shs

Market Capitalization

$16.73 billion

P/E Ratio

14.81

Dividend Yield

3.00%

Beta

0.45